Plant Name: Amomum krervanh
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 2.013E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.595E-09 | 2.187E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.120E-08 | 1.040E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.678E-08 | 1.040E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0065008; regulation of biological quality | 4.541E-07 | 3.756E-04 | CYP19A1, CYP1A1, CYP1B1, FABP3, FABP4, MAPK1, MAPT, PPARA, PPARD, THRB, TLR2, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.942E-07 | 6.281E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.176E-06 | 7.400E-04 | CYP1A1, CYP1B1, MAPK1, TLR2, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.189E-06 | 7.400E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 2.112E-06 | 1.098E-03 | CYP19A1, FABP4, LMNA, MAPK1, MAPT, PPARA, PPARD, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.301E-06 | 1.119E-03 | CYP1A1, CYP1A2, CYP1B1, MAPK1, TLR2, TP53, TRPA1 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 2.520E-06 | 1.164E-03 | CYP1A1, CYP1B1, FABP3, MAPK1, TLR2, TP53, TRPA1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 3.103E-06 | 1.379E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP5, LMNA, MAPK1, PPARA, PPARD, TLR2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.916E-06 | 1.946E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.238E-06 | 2.037E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 6.472E-06 | 2.473E-03 | MAPK1, MAPT, PPARA, THRB, TLR2, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.219E-05 | 3.961E-03 | PPARA, PPARD, THRB |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.267E-05 | 4.058E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.397E-05 | 4.225E-03 | MAPK1, MAPT, PPARA, TP53 |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 1.718E-05 | 4.734E-03 | PPARA, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.138E-05 | 5.609E-03 | PPARA, PPARD, THRB |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.289E-05 | 5.864E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 2.926E-05 | 7.323E-03 | CYP1B1, FABP3, LMNA, PPARD, TLR2, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 3.136E-05 | 7.759E-03 | FABP3, PPARA, PPARD |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.425E-11 | 3.129E-09 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.890E-07 | 1.219E-05 | CYP1A2; CYP1A1; CYP1B1; CYP19A1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 5.923E-06 | 2.547E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.168E-05 | 3.768E-04 | CYP1A1; CYP1B1; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.660E-05 | 9.443E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.185E-05 | 1.115E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.531E-04 | 2.822E-03 | THRB; MAPK1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.536E-04 | 3.590E-03 | LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.181E-04 | 3.516E-03 | MAPK1; PPARA; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.869E-04 | 3.590E-03 | MAPK1; TP53; TLR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.513E-04 | 6.923E-03 | MAPK1; TP53; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.092E-04 | 6.923E-03 | MAPK1; PPARA; TSHR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.144E-04 | 6.605E-03 | MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.062E-04 | 3.590E-03 | MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.145E-03 | 8.498E-03 | MAPK1; TP53 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.451E-03 | 8.782E-03 | MAPK1; MAPT; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.878E-04 | 8.495E-03 | MAPK1; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.186E-03 | 8.498E-03 | MAPK1; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.145E-03 | 8.498E-03 | FABP4; TSHR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.539E-03 | 8.782E-03 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.401E-03 | 8.782E-03 | MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.586E-03 | 8.782E-03 | MAPK1; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.242E-03 | 1.033E-02 | CYP1B1; MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.315E-03 | 1.425E-02 | MAPK1; TP53; TLR2 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.832E-03 | 9.249E-03 | MAPK1; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.634E-03 | 8.782E-03 | MAPK1; TP53 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.539E-03 | 8.782E-03 | CYP1A2; CYP1A1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.936E-03 | 9.249E-03 | MAPK1; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.860E-03 | 1.272E-02 | MAPK1; TP53 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.936E-03 | 9.249E-03 | MAPK1; TLR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.075E-03 | 1.788E-02 | MAPK1; TP53; PPARD |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.028E-03 | 1.624E-02 | MAPK1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.881E-03 | 1.615E-02 | MAPK1; TLR2 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.965E-03 | 1.788E-02 | MAPK1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.130E-03 | 1.788E-02 | MAPK1; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.539E-03 | 2.220E-02 | TP53; TLR2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.130E-03 | 1.788E-02 | MAPK1; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 7.109E-03 | 2.351E-02 | TP53; PPARD |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 9.825E-03 | 3.168E-02 | MAPK1; MAPT |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.436E-02 | 4.308E-02 | MAPK1; TP53 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.097E-02 | 3.453E-02 | MAPK1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.181E-02 | 3.628E-02 | TP53; TLR2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.492E-03 | 1.756E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; THRB |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; MAPK1; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; MAPK1; TLR2 |